文献速递艾滋病与性传播感染

真实世界中一线第二代整合酶抑制剂方案病毒学失败后的结局

Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

这项回顾性研究分析了2016年3月24日至2021年12月31日期间521名初治HIV感染者启动一线第二代整合酶抑制剂方案后的病毒学失败情况。45人(8.6%)在中位14.9个月后失败,其中34人(75.6%)最终达到病毒学成功,维持失败方案者与换药者的病毒学成功曲线无差异。

要点

  • 一线第二代整合酶抑制剂方案病毒学失败率8.6%(45/521)。
  • 失败后75.6%(34/45)达到病毒学成功,维持原方案者占75.8%(25/33)。
  • 维持失败方案与换药者的病毒学成功曲线无差异。

核心结论

  • 多数病毒学失败者维持原失败方案,且多数病例出现自发病毒学抑制。

研究设计与样本

  • 回顾性研究,纳入2016年3月24日至2021年12月31日期间启动一线第二代整合酶抑制剂方案(DTG/3TC、BIC/FTC/TAF、基于DTG的三药方案)并发生病毒学失败的HIV感染者。
  • 共521名初治HIV感染者启动一线第二代整合酶抑制剂方案,其中45人(8.6%)发生病毒学失败。

主要发现

  • 病毒学失败45例:基于DTG的三药方案33/395(8.4%),BIC/FTC/TAF 11/102(10.8%),DTG/3TC 1/24(4.2%)。
  • 失败后中位随访5.13个月,34/45(75.6%)达到病毒学成功:维持失败方案者25/33(75.8%),换药者9/12(75%)。
  • 估算6个月和12个月病毒学成功概率分别为59%和84%。
  • 维持失败方案者与换药者的病毒学成功曲线无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Virological failures of first-line second-generation (SG) INSTI-based regimens are rare, usually characterized by low viremia and absence of drug resistance mutations. OBJECTIVES: To explore the efficacy of rescue regimens introduced after virological failure (VF) to a first-line SG-INSTI therapy. PATIENTS AND METHODS: This was a retrospective study on people living with HIV (PWH) failing a first-line SG-INSTI regimen [DTG/3TC, BIC/FTC/TAF, DTG-based three-drug regimen (DTG-3DR)] between 24 March 2016 and 31 December 2021. Follow-up accrued from the second viral load (VL) ≥ 50 copies/mL under SG-INSTI regimen (baseline) until virological success (VS, achievement of at least one VL < 50 copies/mL after baseline) or last visit. Cumulative probabilities of VS were estimated by Kaplan-Meier curves and compared using a log-rank test. RESULTS: Overall, of 521 naïve PWH who started a first-line SG-INSTI regimen, 45 (8.6%) had VF after a median of 14.9 (IQR = 6.9-25.9) months: 33/395 (8.4%) individuals failed a DTG-3DR, 11/102 (10.8%) a BIC/FTC/TAF and 1/24 (4.2%) failed a DTG/3TC.At baseline, 12/45 (27%) PWH changed antiretroviral therapy [median baseline VL 134 (IQR = 81-233) copies/mL], while 33 (73%) maintained their failing regimen [median baseline VL 75 (IQR = 60-145) copies/mL].During a median follow-up of 5.13 (IQR = 3.8-7.1) months, 34 (75.6%) PWH achieved VS: 25/33 (75.8%) maintaining their failing regimen, 9/12 (75%) switched regimen; the estimated 6- and 12-months probabilities of VS were 59% and 84%, respectively.There was no difference in VS curves between PWH who maintained their failing regimen and those who switched therapy. CONCLUSIONS: Most individuals remained on their failing regimen, achieving spontaneous virological suppression in most cases. These data help to understand a real-life VF scenario in the context of the current SG-INSTI era.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Papaioannu Borjesson R, Clemente T, Diotallevi S, et al. Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting. J Antimicrob Chemother. 2025. PMID: 39568118. doi:10.1093/jac/dkae420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。